Publication | Closed Access

453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study

Phase I/ii StudyDurable Antitumor ActivityMedicineImmunologyAdvanced Solid TumorsTumor TargetingAnti-cancer AgentCancer TreatmentOncologyRadiation Oncology